Loading clinical trials...
Loading clinical trials...
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Oral Ozanimod to Evaluate Efficacy and Long-term Safety in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
Conditions
Interventions
Ozanimod
Placebo
Locations
67
Japan
Local Institution - 104
Sapporo, Hokkaido, Japan
Local Institution - 105
Nishinomiya, Hyōgo, Japan
Local Institution - 156
Okayama, Okayama-ken, Japan
Local Institution - 153
Osaka, Osaka, Japan
Local Institution - 132
Osaka, Osaka-shi, Japan
Local Institution - 131
Iruma-gun, Saitama, Japan
Start Date
June 3, 2019
Primary Completion Date
September 30, 2025
Completion Date
September 30, 2025
Last Updated
October 15, 2025
NCT05076175
NCT06651281
NCT04121806
NCT06065228
NCT06892990
NCT03596645
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions